Are Wegovy and Ozempic the same drug?

DoktorABC editorial team

Accurate, up-to-date health information written by our editorial team and reviewed by UK-registered prescribers.

What is Wegovy and what is it used for?

Wegovy is the brand name for semaglutide at a dose formulated specifically for weight management. It is manufactured by Novo Nordisk and is licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or sleep apnoea.

Treatment starts at 0.25 mg per week and increases gradually over 16 to 20 weeks to the standard maintenance dose of 2.4 mg. A higher dose of 7.2 mg was approved by the MHRA on 6 January 2026 for patients with a BMI of 30 or above who have reached and tolerated the 2.4 mg dose. Wegovy received NICE approval for use within specialist NHS weight management services under Technology Appraisal TA875 in March 2023. For most people, access is currently via private prescription.

What is Ozempic and what is it used for?

Ozempic is the brand name for semaglutide at doses formulated for the management of type 2 diabetes. It is also manufactured by Novo Nordisk and has been available in the UK since 2018. It is licensed by the MHRA specifically for the treatment of type 2 diabetes in adults, when used alongside diet and exercise to improve blood sugar control.

Ozempic is available at doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg, administered once weekly. Eligible patients with type 2 diabetes can access it on the NHS under NICE guidance, paying only the standard prescription charge. It is not licensed for weight management in the UK.

What is the difference between Wegovy and Ozempic?

Though both products contain semaglutide and work through the same mechanism, the differences between them are clinically meaningful.

The higher maintenance dose in Wegovy is not incidental. The dose range used in weight management clinical trials is substantially higher than the doses used for diabetes treatment. This is the primary reason Wegovy produces greater weight loss than Ozempic in practice.

Which is better for weight loss: Wegovy or Ozempic?

Wegovy produces significantly greater weight loss than Ozempic. The primary reason is dose. Wegovy was specifically developed and trialled at higher doses to maximise weight loss, whereas Ozempic's dosing was designed to optimise blood sugar control in type 2 diabetes.

In the STEP 1 trial (New England Journal of Medicine, 2021), participants on Wegovy 2.4 mg lost an average of 14.9% of their starting body weight over 68 weeks. In the STEP UP trial, published in November 2025 and supporting the January 2026 MHRA approval of the 7.2 mg dose, average weight loss reached 20.7% over 72 weeks.

By contrast, Ozempic's maximum licensed dose for diabetes is 2 mg, and the weight loss observed in diabetes trials is meaningfully lower. In clinical trials at the 1 mg dose, average weight loss was around 4.5 kg over 30 weeks, with 52-62% of participants losing at least 5% of their starting body weight after one year. This is a clinically useful outcome in the context of diabetes management, but it is not comparable to the results seen at Wegovy's higher weight-management doses.

Do Wegovy and Ozempic have the same side effects?

Broadly yes, as both contain semaglutide and work through the same mechanism. The key difference is that Wegovy's higher doses mean gastrointestinal side effects can be more pronounced, particularly during the titration phase.

Both share the same serious contraindications: they must not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2), and neither should be used during pregnancy or breastfeeding.

The MHRA updated product information for semaglutide in February 2026 to highlight a very rare risk of non-arteritic anterior ischaemic optic neuropathy (NAION), a sudden reduction in blood flow to the optic nerve that can cause vision loss in one eye, affecting up to 1 in 10,000 people. Patients who notice sudden vision changes in one eye should attend eye casualty or accident and emergency immediately and report the reaction via the Yellow Card scheme at yellowcard.mhra.gov.uk.

How much do Wegovy and Ozempic cost in the UK?

The cost picture differs significantly depending on whether you are accessing treatment on the NHS or privately.

What do Wegovy and Ozempic cost on the NHS?

For eligible patients, both medicines are available at the standard NHS prescription charge of £9.90 per item in England. Prescriptions are free in Scotland, Wales, and Northern Ireland for eligible patients. The routes to NHS access differ significantly, however.

Ozempic is available on the NHS for adults with type 2 diabetes who meet NICE eligibility criteria, including inadequate blood sugar control despite other medications. Wegovy is available on the NHS for weight management through specialist services under NICE TA875, with strict BMI and comorbidity criteria and, in most areas, significant waiting times.

What do Wegovy and Ozempic cost privately?

Prices based on GPhC-registered UK provider data, April 2026.

In straightforward price terms, Ozempic can appear cheaper. However, this comparison is misleading for anyone seeking weight management treatment. Ozempic is not licensed for this purpose in the UK, its maximum dose is lower than Wegovy's weight-management doses, and the clinical outcomes for weight loss at Ozempic's doses are substantially inferior.

Can you use Ozempic for weight loss in the UK?

Ozempic is not licensed for weight loss in the UK. The MHRA has authorised it only for the treatment of type 2 diabetes. Off-label prescribing, where a licensed prescriber issues a medicine for a purpose outside its authorised indication, is legal in the UK and can be appropriate in specific clinical circumstances. However, the regulatory and professional guidance strongly points towards using Wegovy, the licensed option, for weight management.

During the Ozempic supply shortage in 2023, the Department of Health and Social Care issued a national patient safety alert restricting Ozempic to its licensed use, ensuring supply for people with type 2 diabetes who depend on it. While the acute shortage has eased, the principle of prioritising licensed supply for diabetes patients remains embedded in NHS and professional guidance.

What do regulators say about off-label prescribing? 

The General Pharmaceutical Council (GPhC) has confirmed that prescribers and pharmacies operating in ways incompatible with national patient safety guidance will be scrutinised, and enforcement action remains possible. Any prescriber offering Ozempic off-label for weight management should explain this clearly to patients, including the reasons why the licensed alternative, Wegovy, is not being used instead.

Should you choose Wegovy or Ozempic?

The decision framework here is relatively straightforward in the UK context, because the licensed indications point clearly in most cases.

When is Wegovy the right choice?

• Your primary goal is weight management
• You have a BMI of 30 or above (or 27 or above with a weight-related health condition)
• You want a treatment specifically trialled, dosed, and approved for weight loss
• You may be eligible for NHS access through a specialist weight management service
• You want access to the higher 7.2 mg dose option if needed

H3: When is Ozempic the right choice?

• You have been diagnosed with type 2 diabetes
• Your GP has recommended semaglutide for blood sugar management
• You are eligible for NHS access under the diabetes prescribing pathway
• Weight loss would be a beneficial secondary outcome of your diabetes treatment

What if you have both type 2 diabetes and want to lose weight?

Some patients with type 2 diabetes may benefit from both the blood sugar control and the weight loss that semaglutide provides. In this situation, Ozempic is the appropriate licensed route on the NHS. Patients in this group who are not achieving adequate weight loss alongside their diabetes management may wish to discuss with their prescriber whether transitioning to Wegovy, or adding a structured weight management programme, is appropriate.

Final thoughts

Wegovy and Ozempic contain the same active ingredient and work through the same mechanism, but they are distinct medicines with different licensed indications, dose ranges, and clinical evidence bases in the UK. For weight management, Wegovy is the licensed and appropriately dosed option. For type 2 diabetes, Ozempic is the relevant treatment. The distinction is a regulatory and clinical one, not a matter of preference.

Before starting either treatment, speaking with your GP or a UK-registered prescriber about which medicine is clinically appropriate for your situation is the most practical first step. Cost and convenience are relevant factors, but they should be considered alongside clinical suitability rather than in place of it.

FAQ

The DoktorABC medical advisory board

Dr. Roland Ruiken

Medical advisor, Norway

Dr. Viktor Simunovic

Medical advisor, Croatia

To the medical advisory board